Quick Answer
Protalix BioTherapeutics, Inc. reported Long-Term Debt of $912.0 thousand for fiscal year 2014.
Protalix BioTherapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2014 | $912.0K | -61.5% |
| 2013 | $2.37M | -56.3% |
| 2012 | $5.42M | -17.4% |
| 2011 | $6.57M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| December 31, 2014 | $912.0K | -61.5% | -61.5% |
| December 31, 2013 | $2.37M | -56.3% | +530.6% |
| June 30, 2013 | $376.0K | -92.0% | -86.1% |
| March 31, 2013 | $2.70M | — | -50.2% |
| December 31, 2012 | $5.42M | -17.4% | +94.2% |
| September 30, 2012 | $2.79M | -41.0% | -40.3% |
| June 30, 2012 | $4.68M | +5.1% | -28.7% |
| December 31, 2011 | $6.57M | — | +38.6% |
- Protalix BioTherapeutics, Inc. showed a decrease of -61.5% in Long-Term Debt compared to the prior fiscal year.
- Over the 2011–2014 period, Protalix BioTherapeutics, Inc.’s long-term debt has declined by 86.1% (from $6.57 million to $912.0 thousand).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2014 report (Form 10-K), filed with the SEC on March 12, 2015.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: